- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma ; volume:25 ; number:1 ; day:28 ; month:3 ; year:2024 ; pages:1-12 ; date:12.2024
The Egyptian journal of medical human genetics ; 25, Heft 1 (28.3.2024), 1-12, 12.2024
- Creator
-
Mahmoud, Magda Sayed
Khalifa, Mohamed K.
Nageeb, Amira M.
El-Arab, Lobna R. Ezz
El-Mahdy, Manal
Ramadan, Amal
Hashim, Maha
Bakr, Noha M.
Swellam, Menha
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43042-024-00516-3
- URN
-
urn:nbn:de:101:1-2406122111323.307024212927
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mahmoud, Magda Sayed
- Khalifa, Mohamed K.
- Nageeb, Amira M.
- El-Arab, Lobna R. Ezz
- El-Mahdy, Manal
- Ramadan, Amal
- Hashim, Maha
- Bakr, Noha M.
- Swellam, Menha
- SpringerLink (Online service)
Other Objects (12)
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients
AI tool for predicting MGMT methylation in glioblastoma for clinical decision support in resource limited settings
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients
AI tool for predicting MGMT methylation in glioblastoma for clinical decision support in resource limited settings
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients